Highly efficient, In-vivo Fas-mediated Apoptosis of B-cell Lymphoma by Hexameric CTLA4-FasL

Non-Hodgkin lymphomas (NHLs) account for 4% of all malignancies. 5-year survival rate increased to 50% with new treatment modalities, however there is need for new effective treatment for the more aggressive, relapsing forms. Recently, CTLA4-FasL, that can bind to B7 and Fas receptor (Fas), was show...

Descripción completa

Detalles Bibliográficos
Autores principales: Aronin, Alexandra, Amsili, Shira, Prigozhina, Tatyana B, Tzdaka, Kobi, Shen, Roy, Grinmann, Leonid, Szafer, Fanny, Edebrink, Per, Rauvola, Mari-Anne, Shani, Noam, Elhalel, Michal Dranitzki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189725/
https://www.ncbi.nlm.nih.gov/pubmed/25227919
http://dx.doi.org/10.1186/s13045-014-0064-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189725/
https://www.ncbi.nlm.nih.gov/pubmed/25227919
http://dx.doi.org/10.1186/s13045-014-0064-6

Ejemplares similares